MedTrace Logo

Dynamic Monitoring and Characterization of Pelvic by 3D Ultrafast MRI

NCT06577831 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-20

No results posted yet for this study

Summary

Pelvic floor disorders affect a large population of women and are responsible for a significant impairment in their quality of life, but the pathophysiology of these disorders is still poorly understood.

The project proposes to define new ultra-fast 3D MRI sequences to capture the movements of the main pelvic organs. Visualization of 3D volumes is of great importance to clinicians, but data size hinders clinical use.

This study is the first to propose a dynamic 3D representation of pelvic organs, together with quantitative estimates of the deformations undergone.

The method is based on four steps: dynamic acquisition, organ segmentation, temporal reconstruction, quantification and visualization of deformations.

The D3-Pelvis project responds to the challenge of "technologies for health" with dynamic 3D MRI acquisition and 3D modeling, offering prospects for diagnostic aids and simulators.

Conditions

  • Pelvic Deformity

Interventions

DIAGNOSTIC_TEST

dynamic MRI

* MRI sequences will be performed for patients and healthy volunteers i * Vaginal and rectal tagging will be performed using a water-based ultrasound gel. * The gel will be inserted by an authorized person (nurse or doctor) using a syringe with a conical tip and, optionally, a probe. * MRI sequences. * Data analysis and interpretation.

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-25
Primary Completion
2025-02-24
Completion
2025-02-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577831 on ClinicalTrials.gov